The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Summary: Background: The rate of gastric emptying ( GE ) and subsequent release of the incretin hormones, glucagon‐like peptide‐1 ( GLP ‐1) and glucose‐dependent insulinotropic peptide ( GIP ) are critical determinants of postprandial glycaemia in health and type 2 diabetes. Slowing of GE may be the dominant mechanism by which exogenous GLP ‐1, and some GLP ‐1 analogues, improve postprandial glycaemia. Aim: To determine the effect of sitagliptin on GE in healthy subjects, and the relationships between GE with glycaemia and incretin hormone secretion. Methods: Fifteen volunteers (22.8 ± 0.7 years) were studied on two occasions following 2 days dosing with sitagliptin (100 mg/day) or placebo. GE (scintigraphy), glycaemia and plasma GLP ‐1 and GIP (total and intact), insulin and glucagon were measured for 240 min following a mashed potato meal (1808 kJ). Results: There was no difference in GE between sitgaliptin and placebo [50% emptying time (T50): P = 0.4]. Mean blood glucose was slightly less ( P = 0.02) on sitagliptin. Sitagliptin reduced plasma glucagon between 75 and 120 min ( P < 0.05), and increased intact GLP ‐1 ( P = 0.0002) and intact GIP ( P = 0.0001) by approximately twofold, but reduced total GIP ( P = 0.0003) and had no effect on total GLP ‐1 ( P = 0.16) or insulin ( P = 0.75). On sitagliptin the initial rise in blood glucose ( r = −0.66, P = 0.008) and the intact GIP response ( r = −0.66, P = 0.007) were inversely related, whereas the intact GLP ‐1 response was related directly ( r = 0.52, P = 0.05) to the T50. Conclusions: While the effects of sitagliptin on glycaemic control are unlikely to relate to slowing of GE in healthy humans, the rate of GE is a significant determinant of postprandial glycaemia on sitagliptin (Clinical Trial: NCT 00501657).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGlucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“18, 19 Studies using the specific GLP-1 receptor antagonist, exendin (9-39),”
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects
Horowitz, M., Edelbroek, M. A. L., Wishart, J. M., & Straathof, J. W. (1993) · Diabetologia · doi:10.1007/bf00400362 · Cited by 469
Self-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392
Self-citationFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 1×
“18, 19 Studies using the specific GLP-1 receptor antagonist, exendin (9-39),”
Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1×
“18, 19 Studies using the specific GLP-1 receptor antagonist, exendin (9-39),”
MethodEffect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261 · cited 1×
“18, 19 Studies using the specific GLP-1 receptor antagonist, exendin (9-39),”
Self-citationTherapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
Cited by
Relationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335
Self-citationGastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273
Self-citationEffects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Self-citationHuber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
Metadata
- Authors
- Stevens, J. E., Horowitz, M., Deacon, C. F., Nauck, M., Rayner, C. K., & Jones, K. L.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2012-06-28
- Volume
- 36
- Issue
- 4
- Pages
- 379-390
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2083867213
- Cited by
- 45
- References
- 14
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study. https://app.cochat.ai/papers/10.1111/j.1365-2036.2012.05198.x
- The paper
- Stevens, J. E., Horowitz, M., Deacon, C. F., Nauck, M., Rayner, C. K., & Jones, K. L. (2012). The effects of sitagliptin on gastric emptying in healthy humans – a randomised, controlled study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2012.05198.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.